MEET OUR FOUNDER

Esmeralda Gallemore – Founder / Nutritional Expert

Esmeralda Gallemore is currently the founder of two thriving ocular vitamin corporations which as of 2020 are consolidated into EyesandBody.com. She is recognized in the field of eyecare for her accomplishments, with top selling health formulations now globally sold in the EU, Mexico, Canada, and throughout the United States: “Macula and Body Health Complete” was created to help prevent the progression in patients suffering from Macular   degeneration. The newly improved formula now contains nicotinamide riboside (NR), scientifically proven to restore NAD cells and follows the most recent clinical data on Zinc. “Urge-Vite NAD+,” was created for patients in need of performance enhancement and hormonal balance. The newly advanced formula is now upgraded  with the powerful ingredient of NR, nicotinamide riboside (NR), scientifically studied to improve restoration of NAD cellular function and enhances the efficiency of mitochondria. This unique formula also contains D-Aspartic acid shown to boost testosterone in those with lower than normal levels. It helps regulate sleep. “Eyes, hair and body” is an all in one formula for all ages geared towards our younger generation. It helps skin, hair, nails and is an all in one formula for full body wellness. “Nutri- Pick Me Up” was created for optimal hydration with high anti-oxidants like turmeric, ginger, fulvic acid, and humic minerals. It is a very popular powder energy boost mix for on the go.

Esmeralda is the author of three non-fiction books titled, “So, You Think You Know Vitamins: The ABC’s of Nutrition”, “So You Think You Can Tech; 1st Edition”, and "So, You Think You Can Tech 2nd edition:  Retina Patient Work Up”. They are currently available on Amazon, Barnes and Noble, EasyReads, and Kindle.” She is a certified instructor and recruiter of ophthalmic staff both locally and abroad. More importantly, however, is her ability to transfer her success through consulting and marketing services to help guide professionals who want to surpass their goals. For the last 19 years she developed a strong background in the field of ophthalmology with an emphasis in retina. In 2003, she completed a two-year ophthalmology clinical program alongside medical students and ophthalmology residents at the UCLA Jules Stein Eye Institute School of Medicine under the supervision of Drs. Kevin Miller and Bobby Ballenberg.

 

From 2003 to 2006, she was hired by the prestigious Retina Vitreous Associates group as a clinical back office trainer consultant. To further enhance her clinical skills, she completed a program at the University of Santiago Chile, directed by Drs Marta Lechuga Carreno and Dr. Rodrigo Vidal Sabarzo, MD. In 2007, she co-founded Retina Macula Institute in Torrance, CA where she had the privilege to work alongside with Dr. Ron Gallemore MD, PHD, also a co- founder, under his supervision, she published multiple scientific journals, and compiled powerpoint presentations both as an angiographer and as co-lecturer.

In the Spring of 2021 she successfully completed her Integrative Nutrition Health Coach training and is now a Certified Nutritional Health Coach. 

She is internationally-recognized as a lecturer for JCAHPO, AAO, and the OPS. This year, she was recognized for donating free masks, shirts, energy boost packages, and teaching books to the nurses and technicians attending JCAHPO and AAO 2020.  She established a new clinical research department and initially worked as both the clinical research coordinator and as the general clinical research administrator. She eventually assembled a team of undergrads that she herself recruited and trained from scratch. Her responsibilities included and were not limited to coordinating the daily clinical trial activities. As a general administrator, she trained her team in understanding each specific study’s protocols, clinical conduct, scheduling visits, preparation of consent, enrollment logs, medication, and drug logs. She was in charge of putting the final budget in place in collaboration with the pharmaceutical companies, and was always under the supervision of the PI, Dr. Ron Gallemore. She categorized proportioned budget properly, and confirmed the completeness and accuracy of the costs.  Some of the clinical trials that she participated in are noted below:

 

(GRA)General Research Administrator/(CRC) Clinical research coordinator
Study Investigating High Resolution OCT, Multifocal ERG and Microperimetry Outcomes of Monthly vs As Needed Ranibizumab in Neovascular Age-Related Macular degeneration (2008)

(GRA)General Research Administrator/(CRC) Clinical research coordinator Regeneron VIEW1: A Randomized, Double Masked, Active Controlled Phase III Study ofthe Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (2008)

(GRA)General Research Administrator/(CRC) Clinical research coordinator  

Regeneron VIEW1: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (2008)

 

(GRA)General Research Administrator/(CRC) Clinical research coordinator   

Alcon GATE: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Denegation (AMD) (2009)

 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Genentech HARBOR: A Phase III, Double Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (2009)

 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Genentech HORIZON: An open-label, multicenter Extension study to evaluate the safety and tolerability of RANIBIZUMAB in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to RETINAL VEIN
OCCLUSION (RVO) who have completed a genentech-sponsored RANIBIZUMAB STUDY (2009) 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Alcon ALKOR: C-07-43 – A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients (2009) 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Valley Eye Retina PRESERVE: Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease (2009) 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Nepafenac as Adjunctive Therapy for Patients with Clinically Significant Diabetic Macular Edema
(2009)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Regeneron: A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (2010)

(GRA)General Research Administrator/(CRC) Clinical research coordinator  

Allergan: A 12-Month Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 ug Ozurdex as Adjunctive Therapy to Lucentis Compared with Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration
(2010)

 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    Nevanac Ist, Ron Gallemore: Exploratory, Randomized, Controlled Clinical Study Assessing the Efficacy of (2010)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Quan Nguyen READ3: Ranibizumab for Edema of the Macula in Diabetes; Protocol 3 with High Dose – the READ 3 study (2010)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Genentech- MAHALO: A Phase IB/II, Multicenter, Randomized, Single-Masked, Sham-Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients with Geographic Atrophy (2010)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Genentech-SHORE: A Multicenter, Randomized, Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion (2011)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Santen: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye (2011)

 (GRA)General Research Administrator/(CRC) Clinical research coordinator    Novartis-CRFB002A2407: A 16-week evaluation of the novartis health management tool in assessing self-test visual function in patients with AMD treated with Lucentis (2011)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Regeneron- VGFT-OD-1009: A Double-Masked, Randomized, Active- Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular dema (2011) 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Allergan- 1128277 – Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
(2011)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Allergan BDP208397-001: A 12-Month, Multicenter, 2-Stage (Open Label, Dose Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Novartis- CLFG316A2202: A multicenter, multiple dose study to assess the safety, tolerability, serum pharmacokinetics, and efficacy of intravitreal LFG316 in patients with neovascular age-related macular degeneration (2012)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

LUX Biosciences- LX-211-11: A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye (2012)

 (GRA)General Research Administrator/(CRC) Clinical research coordinator    Allergan IST DME IIT-406: a randomized study to test the efficacy of Ozurdex versus Avastin on recalcitrant macular edema and macular function associated with diabetic retinopathy on patients with two or more prior intravitreal anti-VEGF drug injections. (2012)

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Allergan REACH-AGN-150998: A phase 2, randomized, double-masked comparison of the effects and safety of treatment with AGN-150998 and ranibizumab on retinal edema and BCVA in treatment-naïve patients with exudative age-related macular degeneration (AMD). (2012) 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

iDEAL- 2010-007-03-DME: A randomized, multi-center, phase 2 study evaluating the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo-007 as monotherapy or in combination with laser photocoagulation or Ranibizumab in adult patients with Diabetic Macular Edema. (2012) 

(GRA)General Research Administrator/(CRC) Clinical research coordinator    

Alcon- C-10-083: A prospective, double-masked, active-controlled, single dose randomized study to assess the safety, tolerability, and efficacy of ESBA 1008 versus Lucentis in adult patients with exudative age-related macular degeneration (AMD) (2012)

 

Through perseverance, dedication and determination, she created a teaching institute to share her devotion to retina. Esmeralda is considered one of the top trainers not only nationally, but also globally in the field of retina with a specialty in IV’s, Fundus Autofluorescence Imaging, fluorescein and Indocyanine Green angiography, Retinal Fundus Photography, B-Scan Imaging (Eye Cubed), and Optical Coherence Tomography (ONH, macula).

She has taught protocols and analysis of ERGs, VEPs, EOGs, multi focal ERGs, slit lamp exams, visual fields (Goldmann, Octopus 1-2-3, Humphrey).

She has taught over 500 undergraduates from elite universities such as University of California Los Angeles (UCLA), Princeton University, (PU), University of Southern California, (USC), Stanford University, Western University of Health Sciences, University of California San Diego (UCSD), University of California Irvine (UCI), and University of California Riverside (UCR).

 

Her institute consisted of a two-year training program that included but was not limited to, clinical experience, retinal angiography, starting IV’s, identifying retinal disorders through pattern recognition, basic patient work-up, manifest refractions, clinical research, and publication of rare cases.